| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,006 | 0,006 | 17:48 |
The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from Jun 3, 2026. The order book will not change.
| Short name: | ACTI |
| Terms: | Reverse split: 1:100 |
| Current ISIN: | SE0001137985 |
| Last day of trading with current ISIN code: | Jun 2, 2026 |
| New ISIN code: | SE0029278555 |
| First day of trading with new ISIN code: | Jun 3, 2026 |
Nasdaq Stockholm AB, Issuer Surveillance, dl-ilasto@nasdaq.com, +46 8 405 7280
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14:48 | Split and Change of ISIN for Active Biotech AB | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from Jun 3, 2026. The order book will not change.
Short... ► Artikel lesen | |
| Do | Active Biotech AB: Active Biotech announces timetable for reverse share split | The Annual General Meeting in Active Biotech AB (publ) ("Active Biotech" or the "Company") held on May 20, 2026, resolved to carry out a reverse share split 1:100, whereby hundred (100) shares are consolidated... ► Artikel lesen | |
| 20.05. | Active Biotech AB: Annual General Meeting of Active Biotech AB | The Annual General Meeting of Active Biotech was held on May 20, 2026. The following main resolutions were passed.In accordance with the Board of Directors' proposal, it was resolved that no dividend... ► Artikel lesen | |
| 13.05. | Active Biotech AB: European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON | Lund, Sweden - May 13, 2026 Active Biotech (NASDAQ Stockholm: ACTI) today announced positive feedback from the European regulatory authorities and ethics committee regarding the clinical proof-of-concept... ► Artikel lesen | |
| 07.05. | Active Biotech AB: Active Biotech Interim Report Q1 2026 | EVENTS DURING THE FIRST QUARTERThe US Patent Office (US PTO) granted a patent related to a pharmaceutical formulation of tasquinimod (January)Active Biotech receives positive feedback on its clinical... ► Artikel lesen |
